demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID 19 hospitalized
COVID-19 mild to moderate
potential COVID-19 treatments
adjuvant therapies
anticoagulant X-COVID-19
anticoagulant, curative dose ATTACC, ACTIV-4a, and REMAP-CAP ...
heparin at therapeutic dose RAPID ...
anti-inflammatoty and immuno-therapy
anti-inflammatory therapies
clarithromycine Rashad ...
colchicine COL-COVID ...
non-steroidal anti-inflammatory drugs Guzman-Esquivel
Indomethacin Ravichandran Ravichandran
corticosteroids Majmundar Li ...
Immunostimulants drugs
convalescent plasma treatment Libster PLACID
interferon
inhaled interferon
IFN alpha
pegylated interferon-α2b Pandit Shashi Bhushan
interferon / TFF2 Fu
peginterferon Jagannathan
PNB001 Lattmann
neutralizing antibody
casirivimab/imdevimab (Ronapreve) Somersan-Karakaya ... Suzuki
Immunosuppressants drugs
anakinra CORIMUNO-ANA-1
anti-interleukin-6
tocilizumab Capra
janus kinase (JAK) inhibitor
baricitinib Rodriguez-Garcia Cantini
tofacitinib Murugesan
lenzilumab LIVE-AIR ...
Kinase inhibitors
imatinib Covid-19 HUF
antiandrogenic
progesterone Ghandehari
antiviral and associated therapy
azithromycin Rashad A ... Espitia-Hernandez COALITION I Covid-19 Brazil ...
azvudine Ren
bromhexine Li T
chloroquine and derivatives
chloroquine NCT04342650
hydroxychloroquine Zhaowei Chen Min Coalition Covid-19 Brazil I ... NCT04333654 Dubee HC-nCoV ... FACCT Trial Kamran
doxycycline Spoorthi
Ensitrelvir (XOCOVA) Mukae - Phase 2a
favipiravir Udwadia AVIFAVIR Shenoy S Solaymani-Dodaran NCT04542694 Holubar M Dabbous HM IRCT20151227025726N14 // U07 Ruzhentsova T FACCT Trial Shinkai
favipiravir plus interferon Khamis
hydroxychloroquine plus macrolides
azithromycin plus hydroxychloroquine Coalition Covid-19 Brazil I ...
ivermectin Shahbaznejad Soto-Becerra Ahmed Spoorthi Abd-Elsalam Chachar Bukhari Krolewiecki Chaccour Kirti Espitia-Hernandez Babalola I-TECH ... RIVET-COV ... Mayer Glorial F Khan
ivermectin plus doxycycline NCT04523831 ...
lopinavir/ritonavir ELACOI ...
lopinavir/ritonavir, ribavirin and interferon beta-1b Hung et al.
nitazoxanide Silva Rocco Fontanesi
remdesivir GS-US-540-5773 ... GS-US-540-5774, 10 days GS-US-540-5774, 5 days
sofosbuvir and ledipasvir Nourian A
umifenovir (arbidol) Yethindra ELACOI ...
miscellaneous
Cannabidiol Crippa ...
sabizabulin VERU-111
Renin-angiotensin-system-acting agents
discontinuation of ACEI/ARB Lopes ...
Vitamins
Vitamin D Rastogi Espitia-Hernandez
hight dose vitamin D COVIT-TRIAL

12 studies excluded by filtering options 2

5347 Mehra, 2020 2124excludednot a RCThigh risk of bias
5521 Del Amo, 2020 200excludedrisk of bias not avaialble
7070 PHE variants (Technical briefing 12 22 may 2021), 2021 2202excludednot a RCT
7420 PHE (Stowe), 2021 2133excludednot a RCThigh risk of bias
8149 PHE Technical briefing 16 (11/18 June 2021), 2021 2133excludednot a RCThigh risk of bias
8275 Musser, 2021 2130excludednot a RCTrisk of bias not avaialble
8350 Rosenberg, 2021 2130excludednot a RCTrisk of bias not avaialble
8515 Scobie, 2021 2200excludednot a RCTrisk of bias not avaialble
9170 UKHSA report 33 (23 december 2021), 2021 2200excludednot a RCTrisk of bias not avaialble
9176 UKHSA 31 december 2021, 2021 2200excludednot a RCTrisk of bias not avaialble
9214 Southern California (Lewnard), 2022 2130excludednot a RCTrisk of bias not avaialble
9294 UKHSA (report W4- 27 January), 2022 2120excludednot a RCTrisk of bias not avaialble